COVID Articles
A new Phase II clinical trial shows HIPRA’s COVID-19 vaccine, BIMERVAX, administered as a booster dose after two previous doses with Comirnaty (Pfizer/BNTech), induces a broad immune response against multiple SARS-CoV-2 variants in adolescents.
The Centers for Disease Control and Prevention is merging its Influenza Division with the Coronavirus and Other Respiratory Diseases Division to create the Influenza and Respiratory Viruses Division.
Updated COVID-19 vaccines from Moderna, Novavax-Sanofi and Pfizer-BioNTech have been approved by the U.S. Food and Drug Administration.
ccording to three different studies, COVID-19 vaccines were associated with a lower risk of major adverse cardiovascular events (MACE), in addition to other outcomes, particularly among older adults.
A recent study in Taiwan that examined the vaccine effectiveness (VE) against moderate to severe COVID-19 infection in children aged 6 to 11 years found the Pfizer/BioNTech BNT162b2 VE was 69.9 percent and the Moderna mRNA-1273 VE was 75.5 percent during Omicron BA.2/BA.5 predominance in 2022.
Researchers have discovered why the unusual side effect of a blood clot that impacted some recipients of the Oxford/AstraZeneca and Johnson & Johnson COVID-19 vaccines occurred.
A vaccine candidate called GBP511 that builds upon a self-assembling nanoparticle technology has begun human clinical testing in Australia.
According to a study that analyzed the Veteran’s Health Administration records found there is no evidence to suggest COVID-19 vaccination increases the risk of developing idiopathic inflammatory myositis.
In a national cohort study of 28 million individuals, researchers found no increased risk of four-year all-cause mortality in individuals aged 18 to 59 years vaccinated against COVID-19, further supporting the safety of the mRNA vaccines that are widely used worldwide.
A study has found that for patients with certain types of advanced lung or skin cancer, administration of a SARS-CoV-2 mRNA vaccine within 100 days of starting immune checkpoint inhibitors is associated with increased overall survival.
A new study has found people have an increased risk of major cardiovascular events following viral infections such as SARS-CoV-2, influenza, HIV, hepatitis C and varicella zoster virus.